{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T04:12:24Z","timestamp":1783743144352,"version":"3.55.0"},"reference-count":35,"publisher":"Pharmaceutical Society of Japan","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2026,7,8]]},"DOI":"10.1248\/bpb.b26-00019","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T22:14:00Z","timestamp":1783462440000},"page":"1073-1086","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Efficacy and Safety of 15-Valent and 13-Valent Pneumococcal Conjugate Vaccines Alone and in Combination with the 23-Valent Polysaccharide Vaccine: A Systematic Review and Meta-analysis"],"prefix":"10.1248","volume":"49","author":[{"given":"Yuri","family":"Matsumoto","sequence":"first","affiliation":[{"name":"Division of Pharmacodynamics, Faculty of Pharmacy, Keio University, 1\u20135\u201330 Shibakoen, Minato-ku, Tokyo 105\u20138512, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Mihara","sequence":"first","affiliation":[{"name":"Division of Pharmacodynamics, Faculty of Pharmacy, Keio University, 1\u20135\u201330 Shibakoen, Minato-ku, Tokyo 105\u20138512, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Division of Pharmacodynamics, Faculty of Pharmacy, Keio University, 1\u20135\u201330 Shibakoen, Minato-ku, Tokyo 105\u20138512, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayu","family":"Tsubouchi","sequence":"additional","affiliation":[{"name":"Division of Pharmacodynamics, Faculty of Pharmacy, Keio University, 1\u20135\u201330 Shibakoen, Minato-ku, Tokyo 105\u20138512, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Ikegami","sequence":"additional","affiliation":[{"name":"Division of Pharmacodynamics, Faculty of Pharmacy, Keio University, 1\u20135\u201330 Shibakoen, Minato-ku, Tokyo 105\u20138512, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mishu","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Division of Pharmacodynamics, Faculty of Pharmacy, Keio University, 1\u20135\u201330 Shibakoen, Minato-ku, Tokyo 105\u20138512, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanon","family":"Nakabayashi","sequence":"additional","affiliation":[{"name":"Division of Pharmacodynamics, Faculty of Pharmacy, Keio University, 1\u20135\u201330 Shibakoen, Minato-ku, Tokyo 105\u20138512, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Nishimoto","sequence":"additional","affiliation":[{"name":"Division of Pharmacodynamics, Faculty of Pharmacy, Keio University, 1\u20135\u201330 Shibakoen, Minato-ku, Tokyo 105\u20138512, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Mizukami","sequence":"additional","affiliation":[{"name":"Division of Pharmacodynamics, Faculty of Pharmacy, Keio University, 1\u20135\u201330 Shibakoen, Minato-ku, Tokyo 105\u20138512, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Muraishi","sequence":"additional","affiliation":[{"name":"Division of Pharmacodynamics, Faculty of Pharmacy, Keio University, 1\u20135\u201330 Shibakoen, Minato-ku, Tokyo 105\u20138512, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Igarashi","sequence":"additional","affiliation":[{"name":"Division of Pharmacodynamics, Faculty of Pharmacy, Keio University, 1\u20135\u201330 Shibakoen, Minato-ku, Tokyo 105\u20138512, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5934-0670","authenticated-orcid":false,"given":"Yuki","family":"Enoki","sequence":"additional","affiliation":[{"name":"Division of Pharmacodynamics, Faculty of Pharmacy, Keio University, 1\u20135\u201330 Shibakoen, Minato-ku, Tokyo 105\u20138512, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Taguchi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacotherapy, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1\u20132\u20133 Kasumi, Minami-ku, Hiroshima 734\u20138553, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Division of Pharmacodynamics, Faculty of Pharmacy, Keio University, 1\u20135\u201330 Shibakoen, Minato-ku, Tokyo 105\u20138512, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Drijkoningen JJ, Rohde GG. Pneumococcal infection in adults: burden of disease. <i>Clin. Microbiol. Infect.<\/i>, <b>20<\/b> (Suppl 5), 45\u201351 (2014).","DOI":"10.1111\/1469-0691.12461"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Tan TQ. Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines. <i>Clin. Microbiol. Rev.<\/i>, <b>25<\/b>, 409\u2013419 (2012).","DOI":"10.1128\/CMR.00018-12"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Kobayashi M, Leidner AJ, Gierke R, Farrar JL, Morgan RL, Campos-Outcalt D, Schechter R, Poehling KA, Long SS, Loehr J, Cohen AL. Use of 21-valent pneumococcal conjugate vaccine among U.S. adults: recommendations of the advisory committee on immunization practices \u2014 United States, 2024. <i>MMWR Morb. Mortal. Wkly. Rep.<\/i>, <b>73<\/b>, 793\u2013798 (2024).","DOI":"10.15585\/mmwr.mm7336a3"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) van Tonder AJ, Gladstone RA, Lo SW, Nahm MH, du Plessis M, Cornick J, Kwambana-Adams B, Madhi SA, Hawkins PA, Benisty R, Dagan R, Everett D, Antonio M, Klugman KP, von Gottberg A, Breiman RF, McGee L, Bentley SD. Putative novel cps loci in a large global collection of pneumococci. <i>Microb. Genom.<\/i>, <b>5<\/b>, 1\u201312 (2019).","DOI":"10.1099\/mgen.0.000274"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Daniels CC, Rogers PD, Shelton CM. A review of pneumococcal vaccines: current polysaccharide vaccine recommendations and future protein antigens. <i>J. Pediatr. Pharmacol. Ther.<\/i>, <b>21<\/b>, 27\u201335 (2016).","DOI":"10.5863\/1551-6776-21.1.27"},{"key":"6","unstructured":"6) <i>Guidelines for pneumococcal vaccination of adults aged 65 and over -4th edition<\/i>. Japanese Respiratory Society, Infectious Diseases and Tuberuclosis Academic Committee\/Vaccine Working Group\/Japan Society for Infectious Diseases, Vaccine Committee\/Japan Society for Vaccinology, Joint Committee (2023)."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Olarte L, Barson WJ, Barson RM, Romero JR, Bradley JS, Tan TQ, Givner LB, Hoffman JA, Lin PL, Hult\u00e9n KG, Mason EO, Kaplan SL. Pneumococcal pneumonia requiring hospitalization in US children in the 13-valent pneumococcal conjugate vaccine era. <i>Clin. Infect. Dis.<\/i>, <b>64<\/b>, 1699\u20131704 (2017).","DOI":"10.1093\/cid\/cix115"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Yildirim I, Hanage WP, Lipsitch M, Shea KM, Stevenson A, Finkelstein J, Huang SS, Lee GM, Kleinman K, Pelton SI. Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease. <i>Vaccine<\/i>, <b>29<\/b>, 283\u2013288 (2010).","DOI":"10.1016\/j.vaccine.2010.10.032"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Grant LR, Slack MPE, Theilacker C, Vojicic J, Dion S, Reinert RR, Jodar L, Gessner BD. Distribution of serotypes causing invasive pneumococcal disease in older adults from high-income countries and impact of pediatric and adult vaccination policies. <i>Vaccine<\/i>, <b>41<\/b>, 5662\u20135669 (2023).","DOI":"10.1016\/j.vaccine.2023.08.001"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Azuma M, Oishi K, Akeda Y, Morino S, Motoki Y, Hanibuchi M, Nishioka Y. Safety and immunogenicity of sequential administration of PCV13 followed by PPSV23 in pneumococcal vaccine-na\u00efve adults aged \u2265 65 years: comparison of booster effects based on intervals of 0.5 and 1.0 year. <i>Vaccine<\/i>, <b>41<\/b>, 1042\u20131049 (2023).","DOI":"10.1016\/j.vaccine.2022.12.060"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Greenberg RN, Gurtman A, Frenck RW, Strout C, Jansen KU, Trammel J, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-na\u00efve adults 60-64 years of age. <i>Vaccine<\/i>, <b>32<\/b>, 2364\u20132374 (2014).","DOI":"10.1016\/j.vaccine.2014.02.002"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Juergens C, de Villiers PJ, Moodley K, Jayawardene D, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults. <i>Hum. Vaccin. Immunother.<\/i>, <b>10<\/b>, 1343\u20131353 (2014).","DOI":"10.4161\/hv.27998"},{"key":"13","unstructured":"13) Cochrane. \u201cChapter 8: Assessing risk of bias in a randomized trial.\u201d: \u2039https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current\/chapter-08\u203a, accessed 6 September, 2025."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) DerSimonian R, Laird N. Meta-analysis in clinical trials. <i>Control. Clin. Trials<\/i>, <b>7<\/b>, 177\u2013188 (1986).","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Ermlich SJ, Andrews CP, Folkerth S, Rupp R, Greenberg D, McFetridge RD, Hartzel J, Marchese RD, Stek JE, Abeygunawardana C, Musey LK. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-na\u00efve adults \u226550 years of age. <i>Vaccine<\/i>, <b>36<\/b>, 6875\u20136882 (2018).","DOI":"10.1016\/j.vaccine.2018.03.012"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Hammitt LL, Quinn D, Janczewska E, Pasquel FJ, Tytus R, Rajender Reddy KR, Abarca K, Khaertynova IM, Dagan R, Dawson R, McCauley J, Shekar T, Fu W, Pedley A, Sterling T, Tamms G, Musey L, Buchwald UK. Immunogenicity, safety, and tolerability of V114, a 15-valent pneumococcal conjugate vaccine, in immunocompetent adults aged 18-49 years with or without risk factors for pneumococcal disease: a randomized phase 3 trial (PNEU-DAY). <i>Open Forum Infect. Dis.<\/i>, <b>9<\/b>, 1\u201313 (2022).","DOI":"10.1093\/ofid\/ofab605"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Song JY, Chang CJ, Andrews C, Diez-Domingo J, Oh MD, Dagan R, Hartzel J, Pedley A, Li J, Sterling T, Tamms G, Chiarappa JA, Lutkiewicz J, Musey L, Tu Y, Buchwald UK. Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged \u226550 years: A randomized phase III trial (PNEU-PATH). <i>Vaccine<\/i>, <b>39<\/b>, 6422\u20136436 (2021).","DOI":"10.1016\/j.vaccine.2021.08.038"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Mohapi L, Pinedo Y, Osiyemi O, Supparatpinyo K, Ratanasuwan W, Molina JM, Dagan R, Tamms G, Sterling T, Zhang Y, Pedley A, Hartzel J, Kan Y, Hurtado K, Musey L, Simon JK, Buchwald UK. Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV. <i>AIDS<\/i>, <b>36<\/b>, 373\u2013382 (2022).","DOI":"10.1097\/QAD.0000000000003126"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Platt HL, Cardona JF, Haranaka M, Schwartz HI, Narejos Perez S, Dowell A, Chang CJ, Dagan R, Tamms GM, Sterling T, Morgan L, Shi Y, Pedley A, Musey LK, Buchwald UK. A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE). <i>Vaccine<\/i>, <b>40<\/b>, 162\u2013172 (2022).","DOI":"10.1016\/j.vaccine.2021.08.049"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Simon JK, Staerke NB, Hemming-Harlo M, Layle S, Dagan R, Shekar T, Pedley A, Jumes P, Tamms G, Sterling T, Musey L, Buchwald UK. Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged \u226550 years: A randomized phase 3 trial (PNEU-TRUE). <i>Vaccine<\/i>, <b>40<\/b>, 1342\u20131351 (2022).","DOI":"10.1016\/j.vaccine.2021.12.067"},{"key":"21","unstructured":"21) Moore MR, Link-Gelles R, Schaffner W, <i>et al<\/i>. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. <i>Lancet Infect. Dis.<\/i>, <b>15<\/b>, 301\u2013309 (2015)."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Dagan R, Patterson S, Juergens C, Greenberg D, Givon-Lavi N, Porat N, Gurtman A, Gruber WC, Scott DA. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. <i>Clin. Infect. Dis.<\/i>, <b>57<\/b>, 952\u2013962 (2013).","DOI":"10.1093\/cid\/cit428"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Kieninger DM, Kueper K, Steul K, Juergens C, Ahlers N, Baker S, Jansen KU, Devlin C, Gruber WC, Emini EA, Scott DA. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. <i>Vaccine<\/i>, <b>28<\/b>, 4192\u20134203 (2010).","DOI":"10.1016\/j.vaccine.2010.04.008"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Hanquet G, Krizova P, Valentiner-Branth P, <i>et al<\/i>. Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination. <i>Thorax<\/i>, <b>74<\/b>, 473\u2013482 (2019).","DOI":"10.1136\/thoraxjnl-2018-211767"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Ladhani SN, Collins S, Djennad A, Sheppard CL, Borrow R, Fry NK, Andrews NJ, Miller E, Ramsay ME. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000-17: a prospective national observational cohort study. <i>Lancet Infect. Dis.<\/i>, <b>18<\/b>, 441\u2013451 (2018).","DOI":"10.1016\/S1473-3099(18)30052-5"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Fairman J, Agarwal P, Barbanel S, Behrens C, Berges A, Burky J, Davey P, Fernsten P, Grainger C, Guo S, Iki S, Iverson M, Kane M, Kapoor N, Marcq O, Migone TS, Sauer P, Wassil J. Non-clinical immunological comparison of a next-Generation 24-valent pneumococcal conjugate vaccine (VAX-24) using site-specific carrier protein conjugation to the current standard of care (PCV13 and PPV23). <i>Vaccine<\/i>, <b>39<\/b>, 3197\u20133206 (2021).","DOI":"10.1016\/j.vaccine.2021.03.070"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Yeh SH, Gurtman A, Hurley DC, Block SL, Schwartz RH, Patterson S, Jansen KU, Love J, Gruber WC, Emini EA, Scott DA. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. <i>Pediatrics<\/i>, <b>126<\/b>, e493\u2013e505 (2010).","DOI":"10.1542\/peds.2009-3027"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Dagan R, Poolman J, Siegrist CA. Glycoconjugate vaccines and immune interference: a review. <i>Vaccine<\/i>, <b>28<\/b>, 5513\u20135523 (2010).","DOI":"10.1016\/j.vaccine.2010.06.026"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) de Roux A, Schm\u00f6ele-Thoma B, Siber GR, Hackell JG, Kuhnke A, Ahlers N, Baker SA, Razmpour A, Emini EA, Fernsten PD, Gruber WC, Lockhart S, Burkhardt O, Welte T, Lode HM. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. <i>Clin. Infect. Dis.<\/i>, <b>46<\/b>, 1015\u20131023 (2008).","DOI":"10.1086\/529142"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Clutterbuck EA, Lazarus R, Yu LM, Bowman J, Bateman EA, Diggle L, Angus B, Peto TE, Beverley PC, Mant D, Pollard AJ. Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells. <i>J. Infect. Dis.<\/i>, <b>205<\/b>, 1408\u20131416 (2012).","DOI":"10.1093\/infdis\/jis212"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Jackson LA, Gurtman A, van Cleeff M, Frenck RW, Treanor J, Jansen KU, Scott DA, Emini EA, Gruber WC, Schmoele-Thoma B. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. <i>Vaccine<\/i>, <b>31<\/b>, 3594\u20133602 (2013).","DOI":"10.1016\/j.vaccine.2013.04.084"},{"key":"32","unstructured":"32) Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, Hadler S, Pilishvili T. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged \u226565 years: recommendations of the Advisory Committee on Immunization Practices (ACIP), <i>MMWR Morb Mortal Wkly. Rep<\/i>., <b>63<\/b>, 822\u2013825 (2014). \u2039http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25233284\u203a."},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Hayward S, Thompson LA, McEachern A. Is 13-valent pneumococcal conjugate vaccine (PCV13) combined with 23-valent pneumococcal polysaccharide vaccine (PPSV23) superior to PPSV23 alone for reducing incidence or severity of pneumonia in older adults? A clin-IQ. <i>J. Patient Cent. Res. Rev.<\/i>, <b>3<\/b>, 111\u2013115 (2016).","DOI":"10.17294\/2330-0698.1214"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Visser M, van Beek J, Tcherniaeva I, van Rooijen DM, Beckers L, Bijvank E, de Jonge MI, Lockhart SP, Pride MW, Rots N, van Baarle D, den Hartog G, Buisman AM. Age-related decline in IgM responses associate with reduced opsonophagocytic activity following PCV13 vaccination. <i>NPJ Vaccines<\/i>, <b>10<\/b>, 95 (2025).","DOI":"10.1038\/s41541-025-01152-7"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Park S, Nahm MH. Older adults have a low capacity to opsonize pneumococci due to low IgM antibody response to pneumococcal vaccinations. <i>Infect. Immun.<\/i>, <b>79<\/b>, 314\u2013320 (2011).","DOI":"10.1128\/IAI.00768-10"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/7\/49_b26-00019\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T03:29:43Z","timestamp":1783740583000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/7\/49_b26-00019\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b26-00019","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"article-number":"b26-00019"}}